Cogent Biosciences, Inc. (COGT) Free cash flow 2017–2025
Cogent Biosciences, Inc. (COGT) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$266.0MFY2025 · since FY2017: -$26.7M → -$266.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$266.0M | -27.7% |
| FY2024 | -$208.4M | -33.2% |
| FY2023 | -$156.4M | -24.6% |
| FY2022 | -$125.5M | -107.5% |
| FY2021 | -$60.5M | — |
| FY2019 | -$41.5M | -25.8% |
| FY2018 | -$33.0M | -23.5% |
| FY2017 | -$26.7M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More COGT financial trends
COGT RevenueCOGT Net incomeCOGT Net marginCOGT Gross profitCOGT Gross marginCOGT Operating incomeCOGT Operating marginCOGT Operating cash flowCOGT Capital expendituresCOGT Return on equityCOGT Stock buybacksCOGT Dividends paidCOGT Total assetsCOGT Total liabilitiesCOGT Shareholders’ equityCOGT overview →